Medical network - on March 28, recently released the new catalogue of the national health care focused on high clinical value of new drugs and new drug major disease treatment, children's drugs, special drugs such as emergency rescue medicine, occupational disease, especially in the blood hematopoietic anticoagulant, antithrombotic drugs, diabetes, cardiovascular disease treatment drugs, antitumor drug and mental aspects of advancing with The Times. 

 

According to m Intranet HDM system data, September 1, 2016 key cities for the domestic public hospital antithrombotic, condensation of anticoagulation and antiplatelet therapy market hit a new high, predict 2016 cut class, p.a. for Greg lowe, than cut Lu Ding, darby group and pp shaaban five drugs such as sales revenue grew by 52.38% year on year. 

 

The overall market 

 

Seven new anticoagulants 

 

2017 version of the catalog of national health insurance in resistance to antithrombotic drugs is mainly composed of vitamin K antagonists, heparin and platelet aggregation inhibitors, enzymes, direct thrombin inhibitors, direct factor Xa inhibitors and other antithrombotic drugs resistance of seven small classes, including 30 drugs, new added seven drugs, increase the proportion of 30.44%. 

 

Seven new anticoagulants are: direct oral factor Xa inhibitors, pp sand class often release agent, sodium sulfonated reach liver decyl injection, ShuLuo oral often release agent, direct thrombin inhibitor darby group of ester oral often release agent, injection, music class, platelet aggregation inhibitor for the peptide injection, indole Finn oral often release agent. Five drugs are exclusive varieties (see table 1), in addition, the music class and in accordance with the peptide with 2 companies for the production (see table 2 and table 3). 

 

 

 

It is worth mentioning that the national standard of low molecular weight heparin for heparin sodium, the flexor heparin calcium and in accordance with heparin sodium, in other words, the new medical insurance directory of antithrombotic drugs added 10 of chemical drugs, become a highlight blood hematopoietic antithrombotic, anticoagulant drugs. 

 

The global market full of vitality 

 

From 2009 to 2015, the FDA has approved the eight anti-clotting drugs listed. In addition to the class (Edoxaban) in accordance with the degree of sand (Cangrelor), and candy's mayor also polite to company with Japan's daiichi prasugrel oral preparations (Effient), boehringer ingelheim added darby group of acetate tablets (Pradaxa), bayer, Johnson &johnson laval shaaban tablet (Xarelto), astrazeneca's for Greg los tablet (Brilinta), Michael bristol-myers squibb/Pfizer, pp shaaban Eliquis, Merck's walter pasha tablet (Zontivity). 

 

 

 

According to the IMS company database data, a leading global sales of drugs in the fortune 500 list, antithrombotic drug market size of $2015 in 20.3 billion, year-on-year growth of 7.65% a year. TOP 20 drugs sales were $18.465 billion, year-on-year growth of 7.83% a year, and formed the high concentration products. Top 10 varieties were cut shaaban, clopidogrel, according to the north of heparin, o pp shaaban, darby group of ester, atenolol, enzyme/on behalf of knapp for Greg lowe, prasugrel, thanks to aspirin and heparin sodium. 

 

 

 

Domestic market scale of nearly 20 billion yuan 

 

In recent years, the CFDA subsequently approved boehringer ingelheim added darby group of ester capsule (Thai BiQuan), bayer's cut shaaban worship (completed), astrazeneca's for Greg los tablet (Linda), Michael bristol-myers squibb/Pfizer, pp shaaban duly (elle) registration at home, after the drugs listed quickly seize market, objectively promotes the growth of domestic antithrombotic drugs market. 

 

According to HDM system data, 1-3 quarter of 2016 key cities for the domestic public hospital antithrombotic drug market scale up to 2.492 billion yuan, predict 2016 annual sum of 2016 yuan, year-on-year growth of 11.57% a year. 

 

According to m Intranet "domestic urban public hospitals, public hospitals, community health center, the county level in towns and townships, entity pharmacies and shop" three terminal 6 big market data, calculate the antithrombotic drugs market scale of nearly 20 billion yuan in 2016. 

 

 

 

Varieties of structure 

 

The laval shaaban growth of 37.85% 

 

Cutting shaaban was bayer/Johnson listed on the world's first direct oral factor Xa inhibitors. Sand. According to the IMS data of 2015 years, the scale of the global market for 4.861 billion dollars, year-on-year growth of 29.51% a year, the United States occupied the main market share, global 2016 in laval shaaban the size of the market is expected to more than $6 billion. 

 

2009 years cutting class in China, goods duly called:. According to HDM system data, 1-3 quarter of 2016, the domestic main city public hospital, cutting class medicine amount to 157 million yuan, predict 2016 annual sum of 2016 yuan, year-on-year growth of 37.85% a year, the growth rate of year-on-year increase of 9%, is one of the top five main varieties of antithrombotic drugs. 

 

 

 

Darby and ester group increased by 132.85% 

 

Darby and group of ester is Germany boehringer ingelheim developed new anticlotting drugs has many characteristics, October 19, 2010, getting listed on the FDA approved in the United States. Darby and ester group is known as the first listed for 50 years after warfarin anticoagulant oral drug, has been listed on the global 81 countries and regions, is the anticoagulant therapy field, to prevent the potentially deadly blood clots landmark in the field of medicine. Darby and 2015 group of ester global market size of $1.711 billion, year-on-year growth of 7.48% a year. 

 

In February 2013, darby and ester group approved by CFDA registered in China, called tai BiQuan goods. According to the HDM system data, 1-3 quarter of 2016 key cities for the domestic public hospitals than add group of ester medicine amount is 29.25 million yuan, predict the sum of money in 2016, the year is 2016 yuan, increased by 132.85% on the previous year, is one of the highest growth rates of antithrombotic drugs. 

 

On behalf of Greg growth of 62.12% 

 

For Greg los belongs to cyclopentyl triazole pyrimidine class of drugs, is astrazeneca company developed a new, selective small molecule anticoagulants. The drug have FDA approved in July 2011, the goods is called Brilinta. For Greg los former name card for gray, but its and thiophene and pyridine class belongs to the classification of different chemical drugs. For Greg los has fast effect, can directly effect the precursor drugs, is not affected by individual genetic differences and other advantages, and combined with platelet reversible mechanism, recuperate platelet function after drug withdrawal. PLATO study for Greg los curative effect is superior to clopidogrel, recommended by multiple guide at home and abroad as a line. It is understood that for Greg lowe has been 10 international guidelines recommended for the treatment of patients with acute coronary syndrome (acs), including the European society of cardiology (ESC) guidelines, the American college of cardiology (ACC) guidelines and the American heart association (AHA) guidelines, etc. 

 

In November 2012, the CFDA approval for Greg registered in China, acute coronary syndrome (ACS) used to reduce the oral drug therapy of thrombotic events, commodity called Linda. According to incomplete statistics, on behalf of Greg lowe has been approved in the global 85 countries listed, was 29 national health insurance directory contains, will be the clopidogrel and upgrading varieties. According to HDM system data, 1-3 quarter of 2016 key cities for the domestic public hospitals for Greg medicine amount to 63.59 million yuan, is expected to the sum of money in 2016, the year is 2016 yuan, increased by 62.12% over the previous year. 

 

 

 

Than cutting Lu Ding growth of 69.58% 

 

Than cutting Lu Ding (Bivalirudin) is a kind of application in recent years in clinical intravenous use of direct thrombin inhibitor, by The United States, New Jersey, The Medicines company research and development, approved in 2000 listed in The United States, commodity called Angiomax/Angiox. The drug used to prevent the bellows in coronary angioplasty (PTCA) in acute ischemic complications, and again in 2005 approved for use in PTCA postoperative thrombocytopenia caused by heparin and thrombocytopenic thrombosis syndrome. In 2015, according to IMS data than cut Lu Ding global sales of $212 million, showing a dip. 

 

Treated with percutaneous coronary intervention (PCI) in patients, than cut Lu Dingke for alternative heparin. Further research thinks, and on the basis of the heparin anticoagulant solution than than cut lu as the basis of anticoagulant solution increased the risk of myocardial infarction and stent thrombosis, but decrease bleeding risk, which depends on whether to reduced risk of bleeding at the same time the use of platelet glycoprotein IIb/IIIa receptor inhibitor. 

 

In 2011, shenzhen xinli Thai pharmaceutical than cutting first copy is cleared by the CFDA Lu Ding API and its injection and commodity called tegus ning. On May 4, 2014 CFDA approval of jiangsu howson pharmaceutical group than cutting Lu Ding API and its injection, the current domestic only for two. 

 

How much potential for the future of than cut Lu Ding wide divergence of the experts, but there's little doubt that, than cut Lu Ding will be a powerful competitor of heparin. In high security, drug by renal excretion, clinical use and heparin is different, do not need to monitor at any time convenient to use and so on characteristics, than cut Lu Ding market is growing rapidly. According to HDM system data, 1-3 quarter of 2016 key cities for the domestic public hospitals than cutting Lu Ding drug amount is 23.58 million yuan, predict the sum of money in 2016, the year is 2016 yuan, year-on-year growth of 69.58% a year.